Treatment with a 5-hydroxytryptamine 2c receptor (5-HT2CR) agonist, such as the new obesity medication lorcaserin (Arena Pharmaceuticals), restores diminished POMC neuron function and improves obesity [9], [10], [11]. This evidence concerns the gene POMC and obesity due to melanocortin 4 receptor deficiency.